Skip to main content
Fig. 3 | Molecular Neurodegeneration

Fig. 3

From: A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice

Fig. 3

Pharmacokinetics and pharmacodynamics of NB-360 in Beagle dogs. a Exposure of NB-360 in blood and CSF of cannulated dogs (mean ± SD, n = 4) after 0.5 mg/kg p.o. dosing, b concentrations of CSF Aβ40 for the individual dogs, late CSF samples were missing for dogs 1 and 2, c CSF Aβ40 in vehicle and treatment group, expressed as percent of the mean of the -24 h and the -1 h predose values (mean ± SD), d plasma Aβ40 in vehicle and treatment groups

Back to article page